ArticleAnnals of surgical oncology2025
Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nodal Pathologic Response After Neoadjuvant Systemic Therapy in Clinically Advanced Node-Positive (cN2 and cN3) Breast Cancer.Annals of surgical oncology · 2026Article
- Neoadjuvant Dual-Targeted HER2 Therapy and Neoadjuvant Chemo-Immunotherapy is Associated with Improved Nodal pCR and Reduced Axillary Surgery.Annals of surgical oncology · 2026Article
- Article
- Article
- A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-Frontiers in oncology · 2026Article
- Nomogram for predicting axillary pathologic complete response in cN2-3 breast cancer after neoadjuvant chemotherapy.NPJ breast cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNodal pathologic complete response (npCR) after neoadjuvant treatment in patients with node-positive breast cancer (BC) avoids the morbidity of axillary dissection. In this study, we aimed to identify predictors of npCR. PATIENTS AND
methodsAdult women with stage 2-3 BC and clinically positive nodes from 2011 to 2021 in the National Cancer Database who received neoadjuvant chemotherapy followed by surgery within 8 months were included. Predictors of npCR were modeled with multivariable logistic regression.
resultsIn total, 47,483 patients were included: 18,978 (40.0%) with npCR and 28,505 (60.0%) with nodal residual disease (nRD). Median age for the npCR group was 53 years (interquartile range [IQR] 21-90 years) compared with 54 years (IQR 21-90 years, p < 0.001) in the nRD group. Triple negative breast cancer (TNBC) was the most common subtype (53.5%) in the npCR group while ER+/HER2- was the most common (46.5%) in the nRD group, p < 0.001. After adjusting for sociodemographic factors, comorbidities, tumor characteristics, and treatment, younger age (odds ratio [OR] 0.99, 95% confidence interval [CI] 0.99-0.99), ER-/HER2+ compared with TNBC (OR 1.32, 95% CI 1.21-1.44), and receipt of immunotherapy (OR 1.60, 95% CI 1.46-1.74) were associated with npCR. Black patients were less likely to have npCR overall (OR 0.90, 95% CI 0.85-0.95) with TNBC and HER2+ tumors, but more likely in ER+/HER2- tumors.
conclusionsBoth tumor and sociodemographic factors were associated with npCR in patients with BC. Black compared with white patients were more likely to have npCR in the ER+/HER2- subtype but less likely in the hormone receptor-negative and HER2+ subtypes. Mechanisms underlying these differences should be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.